Markus J. Harder

Ulm, BW 89081, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Response to Comment on "Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1".

Response to Comment on "Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1".

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: October 09, 2019

Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1.

Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: November 21, 2018

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.

Journal: Frontiers in immunology

Published: November 09, 2018

IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.

IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.

Journal: Molecular cancer therapeutics

Published: October 23, 2018

Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay.

Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay.

Journal: Transfusion

Published: January 23, 2018

Biophysical analysis of sialic acid recognition by the complement regulator Factor H.

Biophysical analysis of sialic acid recognition by the complement regulator Factor H.

Journal: Glycobiology

Published: November 09, 2017

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Journal: Blood

Published: August 08, 2016

Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

Journal: Immunobiology

Published: September 10, 2015

Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.

Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: August 27, 2015

Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1.

Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1.

Journal: The Journal of biological chemistry

Published: April 08, 2015

Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.

Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.

Journal: Molecular cancer therapeutics

Published: November 08, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026